Savara Inc. Stock
€3.84
Your prediction
Savara Inc. Stock
Pros and Cons of Savara Inc. in the next few years
Pros
Cons
Performance of Savara Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Savara Inc. | 1.050% | 2.128% | -16.157% | 41.176% | -11.111% | 161.224% | -60.343% |
Rockwell Medical Inc. | -2.030% | -3.331% | 12.871% | -53.739% | -7.958% | -80.406% | -96.382% |
Avid Bioservices Inc | - | -9.877% | 1.389% | -50.676% | 19.672% | -58.989% | 113.170% |
Gritstone Oncology Inc | -1.050% | -7.230% | -14.614% | -64.133% | -63.052% | -91.159% | - |
News
Savara to Present at the Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024